Search results for "From ACP Journal Club"


 
Results 1 - 10 of about 135 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo

Based on this and previous trials, low-dose colchicine should be considered as anti-inflammatory therapy for secondary prevention after myocardial infarction (MI) in patients at high risk for cardiovascular (CV) events, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2024/05/10/7.htm
10 May 2024

In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wk

An ACP Journal Club commentary cautioned that although a recent industry-funded trial was designed to approximate real-world practice, certain factors may still limit the generalizability of its findings.
https://diabetes.acponline.org/archives/2024/01/12/7.htm
12 Jan 2024

In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary

A recent systematic review of the beneficial and harmful effects of 15 glucagon-like peptide-1 receptor agonists (GLP-1 RAs) should be helpful to clinicians and suggests which drugs are likely to dominate the market in the next few years, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/05/10/8.htm
10 May 2024

In latent autoimmune diabetes in adults, mortality was similar to T2DM but retinopathy was higher at 5.9 y

If confirmed, the findings of different disease trajectories among patients with latent autoimmune diabetes in adults could eventually merit reclassification of the types of diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/01/12/6.htm
12 Jan 2024

In T2DM with obesity, time-restricted eating increased weight loss and reduced HbA1c level at 6 mo

The small trial comparing time-restricted eating and calorie restriction with control was adequately powered to inform clinical practice, but larger trials with longer follow-up should be done to confirm the results, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/02/09/6.htm
9 Feb 2024

In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk

The new drugs known as “twincretins” represent a major breakthrough for patients with overweight or obesity, prediabetes, or diabetes, but obstacles will include supply, lack of cost-effectiveness evidence, and insurance coverage, an ACP Journal club commentary said.
https://diabetes.acponline.org/archives/2023/11/10/7.htm
10 Nov 2023

In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes

The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on gout in patients with type 2 diabetes or heart failure (HF) may allow reduced polypharmacy when treatment for gout is also needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/11/10/6.htm
10 Nov 2023

In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin

A new study provides some reassurance to patients who unintentionally become pregnant while taking diabetes drugs but should be interpreted with caution because the number of infants exposed was low and only pregnancies resulting in live births were included, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/04/12/7.htm
12 Apr 2024

In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y

An ACP Journal Club commentary noted that it's unknown whether lower-risk and younger statin-intolerant patients would derive the degree of benefit from bempedoic acid found in this study, since the industry-funded trial enrolled only high-risk and older patients.
https://diabetes.acponline.org/archives/2024/04/12/8.htm
12 Apr 2024

In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA1c vs. daily degludec at 26 wk

Weekly insulin icodec has shown potential benefit in recent trials, but data on its effects in patients with type 1 diabetes or renal or hepatic failure are still awaited, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2023/10/13/7.htm
13 Oct 2023

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next